| Literature DB >> 32303981 |
Ruba Bnyan1, Laura Cesarini2, Iftikhar Khan1, Matt Roberts1, Touraj Ehtezazi3.
Abstract
BACKGROUND: Inkjet method has been used to produce nano-sized liposomes with a uniform size distribution. However, following the production of liposomes by inkjet method, the solvent residue in the product could have a significant effect on the properties of the final liposomes.Entities:
Keywords: Ethanol content; Inkjet method; Liposome; Nano- size; PDI; Rotary evaporator
Mesh:
Substances:
Year: 2020 PMID: 32303981 PMCID: PMC7214573 DOI: 10.1007/s40199-020-00340-1
Source DB: PubMed Journal: Daru ISSN: 1560-8115 Impact factor: 3.117
Summary of the prepared formulations, showing the components and the amounts of both reservoir and receiver solutions
| Samples (Abbreviation) | Reservoir solution | Receiver solution | ||
|---|---|---|---|---|
| EPC lipid (mg) | Lidocaine | component | ||
| Blank liposome 1 | (BL1) | 500 | – | Distilled Water |
| Loaded liposome 2 | (LL2) | 500 | 150 | Distilled Water |
| Blank liposome 3 | (BL3) | 500 | – | Tween 80 solution |
| Loaded liposome 4 | (LL4) | 500 | 150 | Tween 80 solution |
| Loaded liposome 5 | (LL5) | 250 | 150 | Distilled Water |
The amounts of EPC lipid and lidocaine are given in 100 ml of ethanol
Fig. 1Image of the in-house inkjet instrument: (a) a typical assembly of the in-house inkjet apparatus, (b) close-up image of inkjet device showing the piezoelectric disk and the nozzle tip
Fig. 2The ethanol percentage in each formulation after using the rotary evaporator for 90 min (blue bars) or after 120 min (red bars), n = 3 and error bars are showing ±SD
Size and charge analysis results of all inkjet-produced formulations. Mean values ± SD, n = 3
| Sample | Before evaporation | After 120 min Evaporation | ||||
|---|---|---|---|---|---|---|
| Size ± SD (nm) | PDI | Zeta potential | Size ± SD (nm) | PDI | Zeta potential | |
| BL1 | 347.73 ± 51.36 | 0.10 ± 0.04 | −6.24 ± 1.05 | 183.30 ± 37.16 | 0.20 ± 0.04 | −16.96 ± 0.57 |
| LL2 | 137.23 ± 4.81 | 0.21 ± 0.01 | −13.66 ± 1.56 | 63.55 ± 4.07 | 0.24 ± 0.01 | −38.26 ± 0.12 |
| BL3 | 90.81 ± 46.24 | 0.25 ± 0.02 | −3.39 ± 0.92 | 64.92 ± 4.31 | 0.45 ± 0.09 | −10.56 ± 0.75 |
| LL4 | 156.56 ± 34.14 | 0.22 ± 0.01 | −17.53 ± 0.98 | 87.32 ± 20.43 | 0.34 ± 0.06 | −37.96 ± 2.43 |
| LL5 | 178.30 ± 12.63 | 0.18 ± 0.03 | −10.30 ± 0.32 | 88.82 ± 3.99 | 0.18 ± 0.03 | −37.40 ± 2.57 |
Fig. 3Illustration of the obtained size distribution of sample LL2; (a) size distribution before ethanol evaporation, (b) size distribution after ethanol evaporation
Fig. 4a and b TEM images of inkjet-produced liposomes before ethanol evaporation, and (c and d) TEM images of inkjet-produced liposomes after ethanol evaporation (90 min). e and f SEM images of inkjet-produced liposomes prior to removing ethanol confirming the spherical and uniform shape of liposomes
Fig. 5Release profiles of lidocaine from ink-produced liposomes (LL2 formulation) versus the control (free drug). Error bars indicate standard deviation (n = 3)